Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Brain Imaging and Cognition Study of CST-103 and CST-139
2020-003796-17Phase 2Unknown
- Sponsor
- CuraSen Therapeutics
- Start
- Sep 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of clenbuterol and tulobuterol in Mild Cognitive Impairment (MCI), Parkinson's disease (PD) and confusion (2 arms), sponsored by CuraSen Therapeutics. Status: unknown.
02
Drugs
clenbuteroltulobuterol
03
Conditions
Mild Cognitive Impairment (MCI)Parkinson's disease (PD)confusion
Beyond the preview
Go deeper on 2020-003796-17.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-003796-17.